Inaugural Vaccine conference hailed a success

Elsevier celebrates the 25th anniversary of its journal Vaccine

Amsterdam, the Netherlands, 3 January 2008 – Elsevier, world-leading publisher of scientific, technical and medical information products and services, organized a conference last month to celebrate the 25th anniversary of its journal Vaccine. With over 350 delegates in attendance from 36 countries and over 70 papers being presented, the stage was set for a landmark 2.5 days in the advancement of the vaccine field.

Vaccine, the pre-eminent journal for researchers interested in vaccines and vaccination, has evolved from a quarterly publication in the early 1980’s into a weekly publication now. It serves as an interface between academics, those in research and development, regulatory and governmental agencies, charities, and health and industry professionals in the field.

In his opening address Youngsuk (YS) Chi, Vice Chairman Elsevier, stated: “The vaccine field has become increasingly multi-dimensional and interdisciplinary, and the conference successfully reflects this trend”.

Especially the recently stopped HIV vaccine STEP trial was a recurring topic during various sessions of the conference. Vaccination is seen as one of the most promising approaches of halting the HIV/AIDS epidemic and the recently published interim results, showing that the vaccine was not effective and did not prevent infection, were discussed during the conference from the science, health and policy perspectives.

Elsevier is looking forward to continuing and strengthening its relationship with the vaccine community, and is delighted to announce that the next Vaccine conference will be held in early December 2008 in Boston, Massachusetts, USA.

# # #

About Elsevier

Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions — among them ScienceDirect, Scopus, Elsevier Research Intelligence,and ClinicalKey—and publishes over 2,200 journals, including The Lancet and Cell, and over 25,000 book titles, including a number of iconic reference works.

The company is part of Reed Elsevier Group PLC, a world leading provider of professional information solutions in the Science, Medical, Legal and Risk and Business sectors, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).

Media Contact:
Floris de Hon
Elsevier
+31 20 485 2498
f.hon@elsevier.com